2025
/
06
/
05
JIC Venture Growth Investments has acquired shares in Sanodyne Therapeutics, Inc. (Sanodyne), through its JIC Venture Growth Fund 2.
Sanodyne is a Japan-originated biotech venture founded with the corporate mission of “relieving the suffering of patients in pain and bringing healing to their daily lives.”
The company’s lead pipeline asset, SNT-001, is a novel therapeutic candidate for peripheral neuropathic pain (PNP), discovered by a domestic company. Through a unique mechanism of action, SNT-001 not only suppresses pain but also promotes repair and regeneration of peripheral nerves, offering the potential for a curative treatment of PNP.
In addition, preclinical studies have shown that SNT-001 does not cause severe central nervous system side effects, a major limitation of existing treatments, positioning it as a highly promising and clinically valuable therapeutic solution. SNT-001 demonstrated high tolerability in a Phase I study conducted abroad, including Japanese participants. The company is currently preparing to initiate a Phase II study in 2026.
Sanodyne was established through collaboration between VGI and its co-investors. Investor involvement from the early stage has ensured timely risk capital provisioning and the strengthening of management foundations.
The significance of this investment can be summarized in three key points:
1. To offer a new therapeutic option for patients with PNP, for whom effective treatments are currently lacking, thereby contributing to improved quality of life.
2. To rapidly commercialize and maximize the value of untapped domestic technological assets through the transfer of technology from an established company to a startup.
3. To promote investor-led company creation, a model already widespread in the U.S., as a sustainable innovation pathway in Japan’s drug discovery ecosystem.
The information contained in this notice is current at the time of publication and subject to change without notice.
